CymaBay Therapeutics Inc (CBAY) Expected to Announce Earnings of -$0.34 Per Share
Wall Street brokerages forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will post earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.30). CymaBay Therapeutics reported earnings of ($0.32) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 6.3%. The firm is expected to report its next earnings results on Tuesday, May 14th.
On average, analysts expect that CymaBay Therapeutics will report full-year earnings of ($1.36) per share for the current year, with EPS estimates ranging from ($1.75) to ($1.13). For the next year, analysts anticipate that the company will post earnings of ($1.48) per share, with EPS estimates ranging from ($2.10) to ($0.70). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover CymaBay Therapeutics.
Several research analysts have commented on the stock. Roth Capital restated a “buy” rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 19th. BidaskClub downgraded CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Zacks Investment Research downgraded CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. ValuEngine raised CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Finally, Leerink Swann began coverage on CymaBay Therapeutics in a research note on Friday, February 22nd. They issued an “outperform” rating and a $22.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. CymaBay Therapeutics presently has an average rating of “Buy” and an average target price of $19.38.
In other news, Director Carl Goldfischer sold 11,675 shares of CymaBay Therapeutics stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $9.02, for a total value of $105,308.50. Following the completion of the transaction, the director now owns 2,335 shares in the company, valued at approximately $21,061.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Meeder Asset Management Inc. raised its holdings in CymaBay Therapeutics by 307.3% in the 1st quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,142 shares during the period. PNC Financial Services Group Inc. grew its position in shares of CymaBay Therapeutics by 23.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,460 shares in the last quarter. Bank of America Corp DE grew its position in shares of CymaBay Therapeutics by 1.5% in the fourth quarter. Bank of America Corp DE now owns 164,192 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 2,478 shares in the last quarter. Citigroup Inc. grew its position in shares of CymaBay Therapeutics by 17.7% in the fourth quarter. Citigroup Inc. now owns 19,966 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Raymond James & Associates grew its position in shares of CymaBay Therapeutics by 7.7% in the fourth quarter. Raymond James & Associates now owns 82,205 shares of the biopharmaceutical company’s stock valued at $647,000 after purchasing an additional 5,899 shares in the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Further Reading: Fiduciary
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.